Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Magen BioSciences

Request full access

Biotechnology company located in 100 beaver street, suite 101, waltham, ma, united states

Waltham, United StatesFounded 2006Biotech & Life Sciences

About Magen BioSciences

Magen BioSciences, Inc. was a biotechnology firm established in 2006, positioning itself in the pharmaceutical sector with a clear focus on dermatology. The company was founded by a distinguished group of scientists and investors, including Rich Aldrich, David Fisher, Phillip Sharp, David Shaw, Christopher Walsh, and Christoph Westphal, who brought together significant experience from academia and the biotechnology industry. Sandra Luikenhuis was also noted as being integral to the founding and growth of the company.

The firm's core business was centered on the research and development of novel pharmaceutical products to improve the health and appearance of human skin. Magen BioSciences operated on a science-driven approach, leveraging a deep understanding of the underlying biology of both normal and diseased skin to identify and develop its therapeutic agents. The company's initial efforts were aimed at addressing conditions such as psoriasis, atopic dermatitis, and acne, as well as pigmentation disorders by exploring the signaling pathways related to melanin production. A key aspect of its strategy involved an exclusive licensing agreement with Eli Lilly & Co. to develop and commercialize a pipeline of preclinical compounds for dermatologic use.

Financially, Magen BioSciences secured a total of $17.2 million in funding over two rounds. The initial seed investment in March 2006 amounted to $1.8 million, co-led by ARCH Venture Partners, TVM Capital, and Venrock Associates. This was followed by a larger Series A round of $15.4 million in April 2006, with Highland Capital Partners as the lead investor. The company's trajectory culminated on April 3, 2009, when it was acquired by Pharmaceutical Product Development (PPD), a global contract research organization, for $14.5 million in cash. This acquisition was intended to expand PPD's compound partnering program into the dermatology market, integrating Magen's dermal biology expertise and compound screening capabilities.

Source: Dealroom company data

Magen BioSciences in the Waltham ecosystem

Live from Dealroom

The Magen BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A5 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Magen BioSciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Magen BioSciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.